NR3C2 and myocardial infarction: The randomized Aldactone evaluation study (RALES) and Eplerenone post-acute myocardial infarction heart and survival study (EPHESUS) are clinical trials that evaluated the role of MR antagonism in patients with severe heart failure and patients with acute myocardial infarction complicated by left ventricular dysfunction, respectively.